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RAPID COMMUNICATION
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A monoclonal antibody marker for Alport syndrome identifies the
Alport antigen as the aS chain of type IV collagen. The nephropathy of
Alport syndrome is associated with unique abnormalities of glomerular
basement membranes and is caused in many families by mutations in
the X-chromosomal gene COL4A5, which encodes the aS chain of type
IV collagen. We have previously reported that Alport epidermal and
glomerular basement membranes fail to bind a monoclonal antibody,
Mab A7, that reacts with normal epidermal and glomerular basement
membranes, and that this abnormality is unique to Alport syndrome.
The molecule in normal tissues that reacts with Mab A7 was termed the
"Alport antigen." In the present study we used recombinant carboxy-
terminal noncollagenous (NC1) domains of the al, a2, a3, a4 and a5
chains of type IV collagen to determine the molecular identity of the
Alport antigen. Mab A7 was found to bind specifically to the NC1
domain of the aS chain of type IV collagen, by ELISA and immuno-
blotting studies. This finding provides a molecular explanation for the
utility of Mab A7 as a marker for the Alport basement membrane
defect. Mab A7 can identify the Alport basement membrane defect in
those patients in whom COL4A5 mutations prevent incorporation of
aS(IV) into basement membranes.
Alport syndrome is a progressive hereditary nephropathy
associated with unique ultrastructural abnormalities of glomer-
ular basement membranes (GBMs). The disease is transmitted
in most families as an X-linked dominant trait [1]. A variety of
mutations have been found in the X-chromosomal gene
COL4AS, which encodes the a5 chain of type IV collagen, in
families with Alport syndrome [2].
Immunohistologic and immunochemical studies of Alport
GBMs have suggested that these are typically deficient in at
least two collagen chains normally present in GBM, the a3 and
a4 chains of type IV collagen [3, 4]. In addition, studies from
our laboratory have indicated that Alport GBM also lacks an
additional collagen chain, which we have termed the Alport
antigen [4—7]. The Alport antigen is identified by a monoclonal
antibody, Mab A7, that reacts with normal GBM, Bowman's
capsule, distal tubular basement membrane, and epidermal
basement membrane [7]. This antibody shows no reactivity
with renal basement membranes or epidermal basement mem-
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branes of most Alport males, and exhibits segmental reactivity
with GBM and epidermal basement membranes of females
heterozygous for Alport syndrome [7]. Mab A7 reacts with a 26
kD monomeric peptide in collagenase digests of normal human
GBM and related dimers, including a cationic dimer that is also
recognized by a monoclonal antibody directed against the
carboxyterminal noncollagenous (NC!) domain of the a3 chain
of type IV collagen [7, 8]. A rabbit antiserum to a non-
consensus sequence of the NC! domain of the aS chain of type
IV collagen appeared to identify the same protein bands in
collagenase-digested normal human GBM as did Mab A7 [7].
Based on these findings we suggested that Mab A7 identifies the
NC! domain of the aS chain of type IV collagen, although direct
proof of this hypothesis was lacking.
Neilson and colleagues recently reported the synthesis of
recombinant NC 1 domains of the al, a2, a3, a4 and aS chains
of type IV collagen, and the specificity of Goodpasture antisera
for the recombinant a3(IV) NC1 domain [9]. The availability of
these recombinant molecules allowed determination of the
specificity of Mab A7. Because the sequence of the NC1
domain of the recently described a6 chain of type IV collagen
has not yet been reported [10], we were unable to include this
protein in the present study. We now report that Mab A7
specifically identifies recombinant a5(IV) NC! domain.
Methods
Recombinant NCJ(IV) proteins
Recombinant al(IV) NC1, a2(IV) NC!, a3(IV) NC!, a4(IV)
NC 1 and a5(IV) NC 1 were expressed as fusion proteins in E.
co/i and purified by affinity chromatography, as previously
described [9]. Recombinant a5(IV) NC1 was also expressed as
a nonfused protein in Baculovirus, using the MaxBac Baculo-
virus Expression System and the transfer plasmid pVL 1392
(Invitrogen, San Diego, California, USA).
Enzyme-linked immunosorbent assay (ELISA)
Fifty to 200 ng of recombinant a!(IV) NC!, a2(IV) NC 1,
a3(IV) NC!, a4(IV) NC! and a5(IV) NCI were coated on
microtiter plates in coating buffer at 37°C overnight. The plates
were washed and then blocked with 2% bovine serum albumin
in coating buffer for six hours at 37°C. The wells were then
incubated with monoclonal antibody A7 (1:16 dilution), or a
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Fig. 1. Enzyme-linked immunosorbent assay of Mab A7 reactivity with
recombinant al-a5(IV) NC! domains. Symbols are (U) A7; (Ill!) con-
trol. Mab A7 exhibits strong reactivity with the NC1 domain of a5(IV).
The control is a mouse monoclonal antibody against the human iC3b
receptor.
monoclonal antibody against human iC3b receptor at the same
dilution, for 24 hours at 37°C. The plates were then washed and
incubated with alkaline phosphatase-conjugated goat anti-
mouse IgG H+L (Caltag, South San Francisco, California,
USA) overnight at room temperature. After washing, disodium
p-nitrophenyl phosphate (Sigma Chemicals, St. Louis, Mis-
souri, USA) was added and absorbance was measured at 410
nm following a 60 minute incubation.
Gel electrophoresis and immunoblotting
Two hundred ng of recombinant al(IV) NC 1, a2(IV) NC 1,
a3(IV) NC1, a4(IV) NC! and a5(IV) NC! were electrophoresed
through an 8 to 18% SDS-polyacrylamide gel, using a discon-
tinuous buffer system [7, 11]. The proteins were then electro-
phoretically transferred to 0.45 m Immobion sheets (Millipore
Inc., Bedford, Massachusetts, USA) in a Biorad vertical blot-
ting apparatus [12]. Immunoblotting was performed as de-
scribed previously with modification [7]. The membranes were
blocked with 5% bovine serum albumin in 0.01 M phosphate,
0.15 M NaCl, pH 7.4 (PBS) overnight at 4°C. The membranes
were washed three times in 0.05 M Tris, 0.15 M NaCl, pH 7.4
containing 0.05% NP-40, and then incubated with monoclonal
antibody A7 (1:20 dilution) for three hours at room temperature.
Mter washing, the membranes were incubated with alkaline
phosphatase-conjugated goat F(ab') anti-mouse IgG H+L
(Caltag) followed by alkaline phosphatase substrate BCIPINBT
(5-bromo-4-chloro-3-indoyle phosphate/nitro blue tetrazoleum)
(Promega, Madison, Wisconsin, USA) in 0.! M sodium carbon-
ate, 0.001 M MgCl2, pH 9.8.
Results
By ELISA, Mab A7 showed strong reactivity with recombi-
nant a5(IV) NC! domain, but minimal or no reactivity with the
NC1 domains of al(IV)-a4(IV) (Fig. 1). Sequential dilution of
a5(IV) NC1 (200. 100, 50, 25 and 12.5 ng) resulted in a
corresponding reduction in absorbance at 410 nm (data not
shown).
Immunoblotting showed that Mab A7 reacted with a5(IV)
NC1 expressed in E. coli (Fig. 2) or Baculovirus (not shown).
No reactivity with the NC1 domains of al(IV)-a4(IV) was seen.
The lower molecular weight material reactive with Mab A7 may
represent degradation of the recombinant protein. Prior studies
have confirmed that Goodpasture sera react with the recombi-
nant a3(IV) NC! [9]. In addition, a previously described
monoclonal antibody against a!(IV) NC!, MBM 10 [13], reacts
only with the al(IV) NC! recombinant protein (not shown).
Discussion
The present findings conclusively demonstrate that the pep-
tide we have termed the "Alport antigen" is in fact the aS chain
of type IV collagen. This identification clarifies several previous
observations. For example, it is now clear that the a3, a4 and
aS chains of type IV collagen are co-distributed in normal
tissues in a pattern distinct from that of the al and a2 chains of
type IV collagen [4, 7, 14—161. This finding, and the concordant
absence of the a3, a4 and aS chains from Alport GBM, support
the hypothesis that these chains may be organized into hetero-
trimeric molecules in selected basement membranes [7, 17—19].
This is further supported by immunochemical studies of normal
human GBM, which demonstrate a cationic noncollagenous
dimer that is recognized by both Mab 17, which identifies the
a3(IV) NCI domain, and Mab A7 [8].
The identification of the Alport antigen as a5(IV) helps to
explain why absence of epidermal basement membrane and
GBM reactivity with Mab A7 is specific for Alport syndrome
[7]. In males, who are hemizygous for COL4A5, mutations in
the gene that prevent the normal incorporation of a5(IV) into
a2 a3 a4 cx5
Fig. 2. Immunoblots of SDS-PAGE gel of recombinant aI-a5(IV) NC!
domains reacted with Mab A?. Mab A7 binds exclusively to the NC!
domain of a5(IV).
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basement membranes would abolish reactivity with Mab A7. In
female heterozygotes, the same mutations apparently produce
mosaic patterns of aS(IV) incorporation into basement mem-
branes and reactivity with Mab A7. Recent studies using a rat
monoclonal antibody against a nonconsensus sequence of
a5(IV) NC1 gave immunohistochemical results similar to those
previously obtained with Mab A7 [20]. Although we have not
correlated COL4A5 mutations and basement membrane reac-
tivity with Mab A7, the predominance of point mutations in
COL4A5 among Alport kindreds suggests that single base-pair
substitutions, as well as more extensive abnormalities such as
deletions, can prevent incorporation of a5(IV) into basement
membranes.
We have previously described anti-GBM alloantibodies gen-
erated by Alport patients following renal transplantation that
mimic Mab A7 in their reactivity with normal human tissues,
Alport skin and kidney, and collagenase digests of normal
human GBM [5, 7, 21]. The present findings suggest that these
alloantibodies are also directed against a5(IV).
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